Activity Overview
HER2-positive gastroesophageal adenocarcinomas (GEAs) have traditionally been associated with limited treatment options and poor prognosis. In the setting of metastatic disease, the introduction of HER2-directed therapy and immunotherapy has led to a dramatic improvement in outcomes for patients. However, appropriate use of these agents requires careful assessment of potentially actionable molecular targets along the treatment continuum, and this necessitates coordination with the molecular pathology team to ensure appropriate tissue stewardship and interpretation of test reports.
In this first of two podcasts focused on HER2-positive advanced or metastatic GEAs, Rohit Gosain, MD; and Rahul Gosain, MD discuss the current treatment landscape, as well as key decision points related to biomarker testing.
Target Audience
This educational program is primarily directed toward medical oncologists, molecular pathologists, radiologists, gastroenterologists, advanced practice providers, and nurses who are involved in the management of patients with advanced or metastatic gastroesophageal adenocarcinomas (GEA).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply best practices for HER2 biomarker testing in patients with GEA to guide timely, individualized treatment decisions
- Incorporate the latest evidence on HER2-directed therapies into individualized treatment plans for patients with advanced GEA
Rahul Gosain, MD, MBA
Medical Director of Wilmot Cancer Institute at Webster
Director of Wilmot Cancer Institute Regional Infusion Services
Assistant Professor of Clinical Medicine
Wilmot Cancer Institute - University of Rochester
Rochester, NY
Disclosures: Consultancy/Advisory: AstraZeneca, Gilead, Janssen Oncology; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD
Rohit Gosain, MD
Director of Roswell Park Care Network Southtowns
Assistant Professor of Clinical Medicine
Roswell Park Comprehensive Cancer Center - University at Buffalo
Buffalo, NY
Disclosures: Consultancy/Advisory: Eisai; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD
Rondell P. Graham, MBBS
Professor of Laboratory Medicine and Pathology
Associate Vice Chair of Test Development
Department of Laboratory Medicine and Pathology
Mayo Clinic
Rochester, MN
Disclosures: Advisor, Consultant, Fee for Service Recipient: Daiichi Sankyo, GSK; Grant/Research Funding: Astellas Pharma
Tanios S. Bekaii-Saab, MD
David F. and Margaret T. Grohne Professor of Novel Therapeutics
for Cancer Research I
Chair, Division of Hematology and Medical Oncology
Mayo Clinic in Arizona
Phoenix, AZ
Disclosures: Research Funding (to institution): Abgenomics, Agios, Arcus, Arys, Atreca, Bayer, Boston Biomedical, Bristol Myers Squibb, Celgene, Clovis, Eisai, Genentech, Incyte, Ipsen, Lilly, Merus, Mirati, Novartis, Pfizer, Seattle Genetics; Consulting (to institution): Arcus, Bayer, Eisai, Genentech, Incyte, Ipsen, Merck, Merus, Pfizer, Revolution Medicines, Seattle Genetics, Servier; Consulting (to self): AbbVie, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Caladrius Biosciences, Celularity, Daiichi Sankyo, Deciphera, Exact Sciences, Exelixis, Foundation Medicine, GSK, Illumina, Janssen, Kanaph, Natera, Sanofi, Sobi, Stemline, Takeda, Treos Bio, Xilio, Zai Lab; IDMC/DSMB: 1Globe, AstraZeneca, Exelixis, FibroGen, Merck/Eisai, PanCAN; Suzhou Kintor, The Valley Hospital; Scientific Advisory Board: Artiva, Immuneering, Imugene, Replimune, Sun Biopharma, Xilis; Royalties: UpToDate; Inventions/Patents: WO/2018/183488: Human PD1 Peptide Vaccines and Uses Thereof: licensed to Imugene; WO/2019/055687: Methods and Compositions for the Treatment of Cancer Cachexia: licensed to Recursion
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
PER is proud to partner with the GI Cancers Alliance.
